Literature DB >> 12243900

Vaccination of cattle with Anaplasma marginale derived from tick cell culture and bovine erythrocytes followed by challenge-exposure with infected ticks.

José de la Fuente1, Katherine M Kocan, Jose C Garcia-Garcia, Edmour F Blouin, P L Claypool, Jeremiah T Saliki.   

Abstract

Anaplasmosis, a hemolytic disease of cattle caused by the tick-borne pathogen Anaplasma marginale (Rickettsiales: Anaplasmataceae) has been controlled using killed vaccines made with antigen harvested from infected bovine erythrocytes. We recently developed a cell culture system for propagation of A. marginale in a continuous tick cell line. In this study, we performed a cattle trial to compare the bovine response to vaccination with A. marginale harvested from tick cell culture or bovine erythrocytes. All immunized and control cattle were then challenge-exposed by allowing male Dermacentor variabilis infected with A. marginale to feed and transmit the pathogen. Nine yearling cattle (three per group) were used for this study and were immunized with cell culture-derived A. marginale, erythrocyte-derived A. marginale or received adjuvant only to serve as controls. Each vaccine dose contained approximately 2 x 10(10) A. marginale and three immunizations were administered at weeks 1, 4 and 6. At week 8, cattle were challenge-exposed by allowing 60 D. variabilis male that were infected with A. marginale as adults to feed on the cattle. Antibody responses of cattle against major surface proteins (MSP) 1a, 1b and 5, as determined by ELISAs, peaked 2 weeks after the last immunization. Cattle immunized with infected IDE8 cell-derived antigens had a preferential recognition for MSP1b while cattle immunized with erythrocyte-derived antigens had a preferential recognition for MSP1a. Protection efficacy was evaluated using the percent infected erythrocytes (PPE), the packed cell volume (PCV), and the prepatent period. A. marginale-immunized cattle showed lower PPE and higher PCV values when compared to control animals and did not display clinical anaplasmosis. The cell culture-derived A. marginale shows promise for use as antigen in development of a new killed vaccine for anaplasmosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12243900     DOI: 10.1016/s0378-1135(02)00206-7

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  10 in total

1.  Use of refrigeration as a practical means to preserve viability of in vitro-cultured IDE8 tick cells.

Authors:  Camila V Bastos; Maria Mercês C das Vasconcelos; Múcio Flávio B Ribeiro; Lygia M Friche Passos
Journal:  Exp Appl Acarol       Date:  2006-06-16       Impact factor: 2.132

2.  Infection and replication of Bartonella species within a tick cell line.

Authors:  Sarah A Billeter; Pedro Paulo V P Diniz; James M Battisti; Ulrike G Munderloh; Edward B Breitschwerdt; Michael G Levy
Journal:  Exp Appl Acarol       Date:  2009-02-26       Impact factor: 2.132

3.  Differential expression and sequence conservation of the Anaplasma marginale msp2 gene superfamily outer membrane proteins.

Authors:  Susan M Noh; Kelly A Brayton; Donald P Knowles; Joseph T Agnes; Michael J Dark; Wendy C Brown; Timothy V Baszler; Guy H Palmer
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

4.  Targeted mutagenesis in Anaplasma marginale to define virulence and vaccine development against bovine anaplasmosis.

Authors:  Paidashe Hove; Swetha Madesh; Arathy Nair; Deborah Jaworski; Huitao Liu; Jonathan Ferm; Michael D Kleinhenz; Margaret A Highland; Andrew K Curtis; Johann F Coetzee; Susan M Noh; Ying Wang; Dominica Genda; Roman R Ganta
Journal:  PLoS Pathog       Date:  2022-05-16       Impact factor: 7.464

Review 5.  Antigens and alternatives for control of Anaplasma marginale infection in cattle.

Authors:  Katherine M Kocan; José de la Fuente; Alberto A Guglielmone; Roy D Meléndez
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

Review 6.  Adaptations of the tick-borne pathogen, Anaplasma marginale, for survival in cattle and ticks.

Authors:  Katherine M Kocan; Jose De La Fuente; Edmour F Blouin; Jose Carlos Garcia-Garcia
Journal:  Exp Appl Acarol       Date:  2002       Impact factor: 2.132

7.  Targeting the tick/pathogen interface for developing new anaplasmosis vaccine strategies.

Authors:  K M Kocan; J de la Fuente; E F Blouin
Journal:  Vet Res Commun       Date:  2007-08       Impact factor: 2.459

8.  Protective immunity induced by immunization with a live, cultured Anaplasma marginale strain.

Authors:  G Kenitra Hammac; Pei-Shin Ku; Maria F Galletti; Susan M Noh; Glen A Scoles; Guy H Palmer; Kelly A Brayton
Journal:  Vaccine       Date:  2013-05-09       Impact factor: 3.641

9.  Infection exclusion of the rickettsial pathogen anaplasma marginale in the tick vector Dermacentor variabilis.

Authors:  José de la Fuente; Edmour F Blouin; Katherine M Kocan
Journal:  Clin Diagn Lab Immunol       Date:  2003-01

10.  Knockout of an outer membrane protein operon of Anaplasma marginale by transposon mutagenesis.

Authors:  Francy L Crosby; Heather L Wamsley; Melanie G Pate; Anna M Lundgren; Susan M Noh; Ulrike G Munderloh; Anthony F Barbet
Journal:  BMC Genomics       Date:  2014-04-11       Impact factor: 3.969

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.